This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk03: Currently, there is no FDA-approved medication for the acute treatment of social anxiety disorder, which is a mental health disorder affecting over 30 million adults in the U.S. And our goal is to fill a major acute treatment gap in SAD with facidinol and deliver new hope and new optimism to the millions of individuals who are anxious and fear embarrassment, humiliation, and judgment when facing SAD. anxiety-provoking social and performance situations in their daily life. Last year, we reported positive results from our Palisade 2 Phase 3 trial of Fasodinol for the acute treatment of SAD. This year, with the goal of complementing the success of Palisade 2, we've initiated our replicate Palisade 3 and Palisade 4 Phase 3 trials on time and as planned. With those milestones now completed, we are now laser-focused on efficient execution toward top-line results from both studies next year. And if successful, we believe either Palisade 3 or Palisade 4, together with Palisade 2, could provide sufficient evidence of safety and efficacy to support the submission of an NDA to the FDA for Fasodinol for the acute treatment of anxiety in adults with SAD. Our iTrueVone program has shown exciting potential as a new, non-systemic, standalone treatment for major depressive disorder, and we are preparing for planned Phase IIb development in the U.S. Based on the Phase IIa clinical data, iTrueVone has the potential to relieve MDD symptoms rapidly and without many of the unwanted side effects associated with current systemic antidepressants, especially weight gain and sexual dysfunction. Our PH80 program for menopausal hot flashes is also progressing. Based on positive phase 2A clinical data, our non-systemic hormone-free farine product candidate has game-changing potential in this major women's health market in which women are faced with a very limited opportunity for treatment options. We're advancing PH80 through the remaining non-clinical programs and CMC requirements to support our submission of a US IND next year. The intent for that is to facilitate our plans for further Phase II development of PH80 for treatment of menopausal hot flashes in the US. I'll now hand the call over to Cindy Anderson, our CFO, to summarize our financials from the last quarter. Cindy?
spk06: Thank you, Sean. As Sean mentioned, I will highlight a few financial results from our fiscal year 2025 second quarter. Research and development expenses were $10.2 million for the quarter ended September 30, 2024, compared to $3.9 million for the same period last year. The increase in R&D expenses was primarily due to an increase in clinical and development expenses related to our Palisade Phase III program for Fasunidol for the acute treatment of SAD, an increase in head count, and an increase in consulting professional services. General administrative expenses were $4.2 million for the quarter ended September 30, 2024, compared to $3.2 million for the same period last year. The increase in G&A expenses was primarily due to an increase in headcount and professional services fees. Our net loss attributable to common stockholders was $13 million for the quarter ended September 30, 2024, compared to $6.6 million for the same period last year. As of September 30th, 2024, we had $97.6 million in cash, cash equivalents, and marketable securities. As a reminder, please refer to our quarterly report on Form 10Q filed with the SEC this afternoon for additional details and disclosures. I will now hand the call back over to Sean.
spk03: Thanks, Cindy. Leveraging our pioneering neuroscience, our deep understanding of nose-to-brain neural circuitry, and multiple positive clinical trials to date. Our referring pipeline has the power and the potential to improve millions of lives who are affected by debilitating effects of neuroscience disorders. To do that by replacing inadequate therapies and setting entirely new standards of care. Our broad and our diverse neuroscience pipeline offers multiple shots at that core goal. And our team is motivated and it's driven by the opportunities to disrupt treatment paradigms, improve lives, and in turn create potential value for our stockholders. So on behalf of everyone at Vistagen, once again, I want to thank you for your continued interest in our efforts and for your support. And we look forward to keeping you informed of our continuing progress.
spk01: Thank you, Sean. Operator, we would now like to open up the call for questions from the cell side analysts participating on the call today.
spk07: Thank you. Ladies and gentlemen, we will now begin the question and answer session. Should you have a question, please press the star followed by the number one on your touchstone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press the star followed by the number two. If you are using a speakerphone, please lift the handset before pressing any keys. One moment, please, for your first question. First question will be coming from Paul Matys from Stifel.
spk02: Hi there. This is Julian on for Paul. Thanks so much for taking my question and congrats on the progress. Just wondering if you could provide a little bit of color on the pace of enrollment so far. What are you hearing from investigators about the demand in enrolling in the study and was wondering if these parallel studies share trial sites or anything else that you could share about the sites that you've chosen for each study. And then lastly, a quick one. Can you just remind us on the timing of when you expect to have data here? Previously, you've said you're targeting mid-25 for PAL-3 and towards the end of 2025 for PAL-4. Just curious if... you're still tracking towards that goal. Thank you.
spk03: Hey, thanks, Julie. I appreciate the question. A couple of things there. I'll try to do them sort of in reverse order. In terms of timelines, still sticking with the guidance that we had previously laid out, as you just articulated, for PAL-3 and PAL-4, respectively. So we're happy that we were able to initiate both of the studies on time, as I noted. middle of the first half of this year for PAL-3 and the middle of the second half of this year for PAL-4. So, you know, there's tremendous excitement across the PIs and the site staffs that we've been able now to bring together for PAL-3 and PAL-4, as you can imagine, on the other side of the PAL-2 success. We've got 16 sites now that are activated for PAL-3 and a dozen for PAL-4. So the color I can give you is, again, this is a very important indication. It's very clear throughout the research community, and a lot of these sites, of course, have psychiatrists that have been treating patients for a very long time, and they just haven't seen anything new. in a very long time, let alone something for the acute treatment of social anxiety disorder, which is so important with this disorder, is enabling people to engage and not have fear of engaging in the things that stress them in their life, that create anxiety and opportunity costs in their life because they're self-isolating or withholding from engaging. It's a really exciting time across both studies. There's no overlap in the sites in either of the two studies. Of course, we've got sites from Palisade 1 and Palisade 2 that we've been very happy with from the past. So I'd say overall, we are really excited to work with our CRO, with the sites, with our internal team. We've really enhanced surveillance. with our own owned assets, as well as augmenting that with what we've got as resources from the CRO. So there's a lot of intense training. There's very close surveillance and adherence to the protocols, which is very important, obviously, to control variability. So I think overall, we're happy with how things are going.
spk08: Josh Prince, you want to add anything to that?
spk04: Yeah, I'd love to add a little bit of color to the PI excitement that you mentioned. We've now had in-person investigator meetings for both Palisade 3 and Palisade 4. And what really comes out there is we have the opportunity to speak with PIs that are there and really express their excitement and enthusiasm to participate in a study like this that's really unlike any other study that they've done before or kind of have come across their plates now. So just want to add that color that we really do see that excitement, enthusiasm, engagement from the PIs and the desire to do these studies.
spk03: It's a good point, and that just came out. We had a recent town hall with the sites. It's something that we do from time to time where it's sort of like a fireside chat with me and with the rest of the team. So keeping the momentum is always key when you're trying to execute efficiently a program, especially with parallel studies in motion. And it always helps when what you're working on is at the leading edge of trying to treat people who have been dealing with this disorder for decades. But thanks for the question, Julian. Appreciate it.
spk07: Next in line will be coming from Andrew Tai from Jeffery.
spk09: Hey, good afternoon. Thanks for the updates. Appreciate you taking my questions. Maybe a tangential question from before that was just asked, but for these phase three studies, both of them that are underway, what are you seeing on the front lines that gives you the confidence? It's definitely different this time for Fasadine. Maybe talk about how sites are operating, the rigor. of these study protocols, whether public speaking challenge is being done correctly and so forth. Thanks.
spk03: Thanks, Andrew. Appreciate the question. You know, one thing, of course, is significantly different now than where we were even during Palisade 2, let alone earlier in that during the pandemic. It's just the ability to have person-to-person contact, to have in-person training, like Josh mentioned, the in-person investigators meetings mean a tremendous amount to be able to regularly and predictably have site visits and also have subjects schedule each phase and each visit during their challenge sequence. It is all different. It is just fundamentally different. The attrition rates that we typically saw before At sites with site staff, we're just not seeing same thing with CROs. You're not seeing the kinds of things that would have been. Frustrating variability coming into, you know, to a protocol that the recipe is pretty clear and when it's followed, it helps tremendously. So that plus things that you'd we've talked about before. I know masks involved no COVID related. potential with the subjects in the study. So there's just fundamental things that are different on a macro basis and then site by site on a micro basis. And just having the ability for the protocol to not be novel. This is something, of course, now that's on the third and the fourth laps within the research community. So the study design isn't new. The endpoint isn't new. So all the things that really helped, I think, with the pace of play and with the ability Really to surveil and to hopefully make sure that we've got rigorous adherence to the protocol across all the sites And John that said um, oh yeah, sorry No, I just want to give Josh a sense to add to adjust and overseas the program primarily So I want to give you a chance Josh anything I missed Sure, we could add to what you said and it kind of builds on the in-person piece, you know in addition to
spk04: to the in-person investigator meetings, you know, we've had an in-person site initiation visit for every site, right? So it's kind of the double reinforcement of training an investigator meeting and then, you know, a good three to four hours with the study staff in their site location, again, hitting all the key details and pieces and components of what it takes to properly execute a public speaking challenge. And then through the monitoring that Sean mentioned, there have been specific examples where we've identified something that wasn't being done quite right, and the next day there's an intervention or a discussion or a retraining or a reminder. So those are the kinds of things that could not happen in our prior Palisade studies and are happening now, which gives us, again, that confidence that we're getting the right patients and that we're reducing variability as much as possible across sites for the public speaking challenge.
spk09: Makes sense. And, you know, in the unfortunate circumstance, should Palisade 3 not hit stats, would you still plan to move forward and complete Palisade 4, just given the turn of events that happened last time with Palisade 1 and 2?
spk03: Yeah, 100%. No question about it, Andrew. The whole program... continues. That's what's the benefit of having a fully funded program. So we're in a spot now where, in the very short order here, we will have initiated everything in 24 that we think we need to read out in 25, and that, if positive, would support our NDA in the early part of 26 for fastidinol. So yes, absolutely 100%, regardless, both studies will be run to completion. Thank you again.
spk08: You bet.
spk07: Our next question will be coming from Miles Minter from William Blair.
spk00: Hey, everyone. Thanks for taking the questions. I've got three, if I may, so bear with me. The first one is just on, I think previously you've Guided towards submitting the the phase 2b protocol in MDD by year-end. Are we still on track for that or is that slightly? You know, maybe looking into next year Second one is in that particular MDD study have you thought about whether like a maybe a caregiver or a physician would be administering the drug versus self administration as I know that that's a consideration between pelt 3 and pelt 4 and Or are you just relying on the fact that multiple doses in that trial probably net that exposure out? And then finally, I'm wondering in the healthy subject data that you just presented at NEI on the depolarization and the electrograms there, did you actually do dosing self-administering or a combination of self-administering versus physician-administered to show that there was actually differences in those electrograms and the exposure of the drug? I know there's a lot there, but would appreciate any thoughts. Thanks. Sure.
spk03: Appreciate the questions, Myles. So as to the first one, we're working very closely with our KOLs and our internal team for that, the Phase IIb protocol. It still is the intention, and we're well down the road with it. We've got some pretty key thoughts already under our belts as to how we want to see that study proceed. A lot of it's simply based on what we saw in the Phase IIa study and what we think are the unique attributes of vitruvone in MDD, and especially as it relates to folks with anxious depression. I think that is a target we likely will hit. If not, it'll just creep maybe a little bit into January, but I think right now we've had a very substantial bit of discussions across all the folks that we want to provide some input, and that protocol is well down the road. So in terms of self-administration, during the study, we don't see that. This is different. This is likely to be a six-week study with... with twice-daily administration, so on an outpatient basis by the folks, so they'll be self-administering it on an outpatient basis. And then as to the last question, Joshua, let's you jump on that one.
spk04: Sure, yeah. The studies that we do in the lab with Dr. Monti, kind of the inventor of pharynx, they're based on physician administration, and they're They really have to be because of the equipment that people are hooked up to. And so, you know, sensors on the frontal lobe or receptors kind of in the nasal cavity, those things require a lot of precision to do the measurements and to reduce noise in those capture of data. And so for that reason, it has to be physician-administered.
spk03: Those studies are conducted here in our headquarters in South San Francisco, and so the subjects are laying down, and the electrodes are placed inside and up by the bridge of their nose, right where the olfactory bulbs are. So as Josh noted, they're very sensitive, and that's the best way to do it, is just to have the IP administered by Dr. Monti and the team.
spk00: Thanks. A ton of sense. Thanks for the questions. Congrats on the progress.
spk08: Thanks.
spk07: Again, if you have any questions, please press star 1, and your hand will be raised. Our last question for today will be coming from Madison Elzadi from B. Riley Securities.
spk05: Hey, guys. Congrats on all the progress, and I appreciate you taking my questions. I guess, could you remind us what's gating to the hot flash study as well as a bit of a follow-up to the prior question? What's really gating to that Phase IIb? And then, secondly, I know it's in the PR, you mentioned an increase in head count, so I was just wondering if this was just kind of related to general activities across the enterprise, or if that was more related to one specific program? Thanks.
spk03: Great. Thanks for the questions. Really appreciate it. So a couple things. So as to the gating for the PH80 study in vasomotor symptoms or hot flashes due to menopause, what we're doing now is a US IND enabling program. So to bring that study The initial study was done in Mexico, and to bring the program into the United States, we're doing just the typical requisite non-clinical studies, CMC-related studies, tox studies that bridge some of the older work, and then, of course, the CMC, because we had to make an entirely new supply of PH80 for the clinical program. So that's what's in motion in order to put us into position to then submit an IND that would leap us right back into phase two development in the U.S. So likely phase, further phase two development, but just in hot flashes. We have positive data in PMDD, but hot flashes is the main direction given what we see is the tremendous opportunity there for really nothing that we see that is non-systemic and what's hormone free. The NK3 antagonists do have some limitations. So that CMC work, non-clinical work, puts the regulatory package in place, and that should be sometime in the second quarter, I think, is our target for that at this point. And then as to the MDD study, again, finalizing the protocol is really what's left there, and then we have an IND that's already open. We've got phase one support for the supply that we built. that we produced, and again, with these, when we acquired these, we had to really go back to the beginning and do the CMC work necessary to enable the clinical work and the regulatory packages. So all those boxes have been checked, and so I think we're on the final lap of the preparations up front of the MDD study. And then headcount-wise, you know, we're about 50 right now, and as you can imagine, we're as we have expanded clinical work and we've got a little bit of additional G&A support that's needed, but most of it's R&D related. A lot of it relates to owning, especially the surveillance and the training that's associated with the PASA 3 program, trying to decouple some of that reliance that was a little bit more variable than we wanted to see during the pandemic. So that allows us to really have own competence and own consistent surveillance, especially for the Palisade Phase 3 program, and, of course, other things related to some of the pre-commercial activities on the CMC side, especially. So a little bit in headcount on the G&A side on finance, but for the most part, it's an R&D increase that's enabling us to do quite a bit more across each of the lead developmental programs that we've got.
spk08: Got it. Very helpful. Thanks, guys.
spk01: Operator, I believe that's all the time we have for questions today. Thank you, everyone. At this time, if you have any additional questions, please do not hesitate to contact us via email at ir.vistagen or via the contact section of our website. We also encourage you to register email updates on our website to stay connected to the latest news. Again, thank you for participating on the call today. We appreciate everyone's interest and support. We look forward to keeping everyone updated on our ongoing progress.
spk08: This concludes our call. Have a great day.
spk07: This concludes our conference call for today. We thank you for participating and ask that you please disconnect your lines. Have a great one, everyone.
Disclaimer